Related references
Note: Only part of the references are listed.Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials
Francois Raffi et al.
AIDS (2015)
Comparative Safety and Neuropsychiatric Adverse Events Associated With Efavirenz Use in First-Line Antiretroviral Therapy: A Systematic Review and Meta-Analysis of Randomized Trials
Nathan Ford et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2015)
Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial
Sharon Walmsley et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2015)
Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV
Christopher E. Kandel et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2015)
Will drug resistance against dolutegravir in initial therapy ever occur?
Mark A. Weinberg et al.
FRONTIERS IN PHARMACOLOGY (2015)
Dolutegravir: Clinical and Laboratory Safety in Integrase Inhibitor-Naive Patients
L. Curtis et al.
HIV CLINICAL TRIALS (2014)
Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study
Bonaventura Clotet et al.
LANCET (2014)
Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis
Zara Shubber et al.
AIDS (2013)
Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study
Hans-Juergen Stellbrink et al.
AIDS (2013)
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
Pedro Cahn et al.
LANCET (2013)
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study
Francois Raffi et al.
LANCET (2013)
Dolutegravir plus Abacavir-Lamivudine for the Treatment of HIV-1 Infection
Sharon L. Walmsley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
World Health Organization Guideline Development: An Evaluation
David Sinclair et al.
PLOS ONE (2013)
Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial
Jan van Lunzen et al.
LANCET INFECTIOUS DISEASES (2012)
GRADE guidelines: A new series of articles in the Journal of Clinical Epidemiology
Gordon H. Guyatt et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
PLOS MEDICINE (2009)
Share Paper
